ALK and non-small cell lung carcinoma: Alectinib has improved ALK inhibition and blood brain barrier transport when compared with crizotinib and reports show an longer median progression free survival (35–37) as well as an improved safety profile in NSCLC compared with crizotinib (36, 38).